The Canadian company reported adjusted earnings per share of four cents in Q2, versus a loss of five cents in Q2 2022) shares also saw gains after beating third-quarter profit
estimates, but lowering its full-year guidance. The drugmaker is gaining momentum from its diabetes drug Mounjaro, though it still lacks regulatory approval for obesity treatment.